Shilpa Medicare is currently trading at RS. 906.80, rising by 36.10 points or 4.15% from its previous close of RS. 870.70 on the BSE.

The stock opened at RS. 886.00 and recorded a high of RS. 914.20 and a low of RS. 871.25 during the session. So far, 18,684 shares have been traded on the counter.

A BSE group 'T' stock with a face value of RS. 1, Shilpa Medicare touched a 52-week high of RS. 1003.20 on June 16, 2025, and a 52-week low of RS. 530.50 on April 7, 2025. In the past week, the scrip’s high and low stood at RS. 915.95 and RS. 841.25, respectively. The company’s current market capitalization is RS. 8740.55 crore.

Promoters hold 44.23% stake in the company, while institutions and non-institutions hold 18.52% and 37.25%, respectively.

The rally comes after Shilpa Medicare received GMP certification from the Saudi Food and Drug Authority (SFDA) for its Unit VI facility in Dabaspet, Bengaluru. The certification follows a full GMP inspection conducted from February 18 to February 20, 2025, which concluded with ZERO observations. The audit focused specifically on Ondansetron Oral Film drug product.

This facility is involved in manufacturing, testing, storage, and release of Oral Films and Transdermal Patches. Oral Films from this site are currently supplied to the US, Australia, and other emerging markets. The site also holds approval from the European Medicines Agency following a recent inspection by Finnish regulators.

Shilpa Medicare specializes in producing and exporting high-quality Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products, and specialty chemicals, using advanced technology and adhering strictly to international standards.